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Zhiyuan ShenCancer is a disease that showcases great molecular diver-
sity among many individuals. Patients with the same clini-
cally diagnosed cancer often vary in their response to the
same treatment because each case of cancer has a unique
molecular signature and pathological evolution. Therefore,
individualized therapy is paramount for improving of can-
cer treatment. The development of rationalized and indivi-
dualized therapy is reliant on the identification of the
specific biomarkers, validation of the biomarkers to iden-
tify the therapeutic targets, and drug development against
the identified targets.
Cancer biomarkers are the measurable molecular changes
to either cancerous or normal tissues of patients. Although
the term “biomarker” most commonly refers to altered ex-
pression of certain gene products or abnormal DNA confi-
gurations, changes to cellular processes such as energy
metabolism and DNA damage response can also be used as
biomarkers in a broader sense. Cancer biomarkers have
multiple implications in cancer intervention. A reliable bio-
marker can be used for cancer diagnosis, risk and prognosis
assessments, and for the surveillance of treatment effective-
ness. More importantly, some, but not all, biomarkers can
be exploited as therapeutic targets. This is because some
biomarkers may be simply “messengers” that do not di-
rectly contribute to the tumor growth and are thus not
ideal therapeutic targets. Only the “driver” or “conspirator”
biomarkers that directly contribute to tumor growth may
be targeted for therapy. Therefore, effort in the develop-
ment of targeted therapies must not simply to identify bio-
markers, but also to understand the biological significance
of such markers in order to validate their usefulness as po-
tential therapeutic targets. In this special issue of Cancer
Biomarkers and Targeted Therapies, we present 5 reviewers
that offer a glimpse of the various topics in cancer bio-
marker and targeted therapy research.
A universal cancer biomarker is the Warburg effect, the
shift of mitochondrial energy production to a glycolysis
dependent metabolism that provides not only energy forCorrespondence: shenzh@umdnj.edu
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reproduction in any medium, provided the orcells but also produces intermediate building materials for
cancer cells to grow. Multiple regulators control this switch
of energy metabolism. The article by Liang et al. summa-
ries the current understanding on how the tumor suppres-
sor gene p53 controls the cellular energy metabolism [1].
Altered DNA repair capabilities are considered a func-
tional biomarker. Like normal cells, cancer cells encounter
various forms of endogenous and exogenous DNA da-
mage. Proper functions of multiple DNA repair pathways
are essential for cancer cells to sustain their growth and
resist therapeutic DNA damage. Defective DNA repair not
only contributes to genomic instability and tumorigenesis
[2], but also offers opportunity for targeted therapy. It is
known that some cancers with defects of a primary DNA
repair pathway may be reliant on an alternative or backup
DNA repair pathway(s). This offers a possibility to target
the alternative DNA pathways, which would confer syn-
thetic lethality to the cancer cells harboring the original
repair defect. The articles by Santivasi and Xia [3] and by
Zhang [4] in this special issue discuss how to exploit the
distinct roles of homologous recombination and non-
homologous end joining in DNA double strand break
repair and the function of homologous recombination in
DNA single strand break repair for targeted therapies.
In addition, two papers in this special issue discuss the
roles of specific genes in the context of cancer progression
and therapy. The paper by Yue et al. [5] discusses the pros
and cons of using cytoskeleton protein filamin-A as a can-
cer biomarker and potentially a therapeutic target. Lastly,
the paper by Allaj et al. [6] summarizes the roles of cyclo-
oxygenase and prostanoid signaling in cancer progression
and as therapeutic target for the treatment.
Due to the broad nature of cancer biomarkers and tar-
geted therapies, it is not our intention to cover all major
aspects of this active research area in a single issue. How-
ever, we hope that these articles offer readers a flavor of
how alternations of specific genes, DNA damage response,
and energy metabolism may be used as cancer biomarkers
and for targeted therapies.is is an Open Access article distributed under the terms of the Creative
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